Xifaxan: profile and news

Salix Pharmaceuticals Reports 1Q2006 Results  May 4, 2006
...interval. XIFAXAN revenue for the first quarter of 2006 was $6.6 million, a 153% increase compared to the first quarter of 2005. ... - Genetic Engineering News,

Salix Pharma 1Q Profit Up 9 Percent  May 4, 2006
...to $39 million as research and development costs more than doubled because of enrollment in a clinical trial for the irritable bowel syndrome treatment Xifaxan ... - MSN Money

Salix Q1 EPS Rises On Surged Revenues, Yet Misses Estimates ...  May 4, 2006
...last-year quarter. The $6.6 million revenue generated by XIFAXAN was 153% up, compared to the prior-year quarter. Revenues from ... - Trading Markets,

Salix Pharmaceuticals to Present at Two Investment Conferences ...  May 8, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), OSMOPREP(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). MOVIPREP(R) and granulated mesalamine are under ... - Genetic Engineering News,

Salix Announces Completion of OsmoPrep(TM) versus Liquid Bowel ...  Apr 19, 2006
Salix also markets COLAZAL(R) (balsalazide disodium) Capsules 750 mg, XIFAXAN(R) (rifaximin) tablets 200 mg, VISICOL(R) Tablets (sodium phosphate monobasic ... - Genetic Engineering News,